24/7 Market News Snapshot 26 August, 2025 – Allarity Therapeutics, Inc. Common Stock (NASDAQ:ALLR)

August 26, 2025

DENVER, Colo., 26 August, 2025 (www.247marketnews.com) – (NASDAQ:ALLR) are discussed in this article.
Allarity Therapeutics, Inc. (ALLR) has experienced a notable surge in pre-market trading, with shares up 46.18% to $1.376 from the previous close of $0.941, driven by a trading volume of 20.61 million shares. This bullish trend indicates heightened investor enthusiasm and optimism surrounding the company’s recent advancements, particularly in the field of oncology.

In a pivotal announcement, Allarity revealed that its investigational therapy, stenoparib, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of advanced ovarian cancer. This designation is crucial as it aims to expedite the development of promising therapies addressing serious medical conditions and significant unmet needs in patient care.

Thomas Jensen, Chief Executive Officer of Allarity, emphasized the importance of this designation, stating, “Receiving the Fast Track designation for stenoparib highlights the compelling need for new treatment options for women battling advanced ovarian cancer.” He expressed eagerness to collaborate with the FDA throughout the clinical development process.

Allarity is actively enrolling participants in a Phase 2 clinical trial to assess stenoparib’s efficacy in treating advanced, recurrent, platinum-resistant, or platinum-ineligible ovarian cancer. Initial patient enrollment began in June 2025, building upon previous Phase 2 data that indicated a durable clinical benefit, with some patients remaining on treatment for over 22 months.

Stenoparib, a dual-targeted inhibitor disrupting PARP1/2 and tankyrase 1/2, presents further opportunities for personalized medicine. Allarity employs its Drug Response Predictor (DRP®) technology to identify patients who may benefit most from this innovative therapy. Holding exclusive global rights to stenoparib’s development and commercialization, Allarity is poised to make significant strides in cancer treatment, showcasing its commitment to advancing healthcare solutions for patients in need.

Related news for (ALLR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.